Gilead Sciences Inc., adjusted current assets

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Current assets	16,085)	14,443)	14,772)	15,996)	30,296)
Adjustments
Add: Allowances for credit losses	56)	55)	47)	44)	40)
After Adjustment
Adjusted current assets	16,141)	14,498)	14,819)	16,040)	30,336)

Download chart

Gilead Sciences Inc., adjusted total assets

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total assets	62,125)	63,171)	67,952)	68,407)	61,627)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Add: Allowances for credit losses	56)	55)	47)	44)	40)
Less: Deferred tax asset²	1,196)	1,241)	1,339)	1,302)	1,556)
After Adjustment
Adjusted total assets	60,985)	61,985)	66,660)	67,149)	60,111)

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Deferred tax asset. See details »

Download chart

Gilead Sciences Inc., adjusted total liabilities

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total liabilities	39,376)	41,962)	46,888)	50,186)	38,977)
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Less: Deferred tax liability²	1,588)	2,673)	4,356)	3,914)	—)
After Adjustment
Adjusted total liabilities	37,788)	39,289)	42,532)	46,272)	38,977)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Deferred tax liability. See details »

Download chart

Gilead Sciences Inc., adjusted total Gilead stockholders’ equity

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Total Gilead stockholders’ equity	22,833)	21,240)	21,069)	18,202)	22,525)
Adjustments
Less: Net deferred tax assets (liabilities)¹	(392)	(1,432)	(3,017)	(2,612)	1,556)
Add: Allowances for credit losses	56)	55)	47)	44)	40)
Add: Noncontrolling interest	(84)	(31)	(5)	19)	125)
After Adjustment
Adjusted total stockholders’ equity	23,197)	22,696)	24,128)	20,877)	21,134)

¹ Net deferred tax assets (liabilities). See details »

Download chart

Gilead Sciences Inc., adjusted capitalization table

US$ in millions

	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Current portion of long-term debt and other obligations, net	1,798)	2,273)	1,516)	2,757)	2,499)
Long-term debt, net, excluding current portion	23,189)	22,957)	25,179)	28,645)	22,094)
Total reported debt	24,987)	25,230)	26,695)	31,402)	24,593)
Total Gilead stockholders’ equity	22,833)	21,240)	21,069)	18,202)	22,525)
Total reported capital	47,820)	46,470)	47,764)	49,604)	47,118)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Add: Operating lease liabilities, current (classified as Other accrued liabilities)²	125)	111)	101)	107)	99)
Add: Operating lease liabilities, noncurrent (classified as Other long-term obligations)³	546)	467)	489)	608)	626)
Adjusted total debt	25,658)	25,808)	27,285)	32,117)	25,318)
Adjustments to Equity
Less: Net deferred tax assets (liabilities)⁴	(392)	(1,432)	(3,017)	(2,612)	1,556)
Add: Allowances for credit losses	56)	55)	47)	44)	40)
Add: Noncontrolling interest	(84)	(31)	(5)	19)	125)
Adjusted total stockholders’ equity	23,197)	22,696)	24,128)	20,877)	21,134)
After Adjustment
Adjusted total capital	48,855)	48,504)	51,413)	52,994)	46,452)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Operating lease liabilities, current (classified as Other accrued liabilities). See details »

³ Operating lease liabilities, noncurrent (classified as Other long-term obligations). See details »

⁴ Net deferred tax assets (liabilities). See details »

Download chart

Gilead Sciences Inc., adjusted net income attributable to Gilead

US$ in millions

12 months ended:	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
As Reported
Net income attributable to Gilead	5,665)	4,592)	6,225)	123)	5,386)
Adjustments
Add: Deferred income tax expense (benefit)¹	(995)	(1,555)	(112)	(223)	(2,109)
Add: Increase (decrease) in allowances for credit losses	1)	8)	3)	4)	—)
Add: Other comprehensive income (loss), net	26)	(81)	143)	(145)	5)
Add: Comprehensive income (loss), net of tax, attributable to noncontrolling interest	(52)	(26)	(24)	(34)	(22)
After Adjustment
Adjusted net income	4,645)	2,938)	6,235)	(275)	3,260)

¹ Deferred income tax expense (benefit). See details »

Download chart

Gilead Sciences Inc. (NASDAQ:GILD)

Adjustments to Financial Statements